Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2012 Earnings Results

Alnylam Pharmaceuticals Misses on EPS, Stock Up 2.27%

Alnylam Pharmaceuticals reported a loss that was worse than expected, with an EPS of $-0.25. Despite this miss, the stock rose by 2.27%, indicating that investors may be optimistic about future prospects or other factors not reflected in the earnings report.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.25	N/A	-36.61%
Revenue	—	N/A	—

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

Alnylam Pharmaceuticals Misses on EPS, Stock Up 2.27%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS, Stock Up 2.27%

Key numbers

Management commentary